we created multigene haplotypes consisting of the genes DRB1, DQA1, and DQB1. Although none of the haplotypes were associated with glioma in additive models, inclusion of a dominance term significantly improved the model for multigene haplotype HLA-DRB1*1501-DQA1*0102-DQB1*0602 (P = 0.002). Heterozygous carriers of the haplotype had an increased risk of glioma [odds ratio (OR) 1.23; 95% confidence interval (CI) 1.01-1.49], while homozygous carriers were at decreased risk compared with non-carriers (OR 0.64; 95% CI 0.40-1.01). Our results suggest that the DRB1*1501-DQA1*0102-DQB1*0602 haplotype may contribute to the risk of glioma in a non-additive manner, with the positive dominance effect partly explained by an epistatic interaction with HLA-DRB1*0401-DQA1*0301-DQB1*0301.
Introduction
Glioma accounts for ~80% of all primary malignant brain tumors and ~13,000 deaths in the United States annually [1] . With ionizing radiation being the only preventable exposure strongly linked to gliomagenesis, the etiology of glioma is largely unknown [2] . Epidemiologic studies have described potential links between glioma and risk of allergies, rosacea, and autoimmune disorders [3] [4] [5] [6] , leading to the hypothesis that genetic variants in immunologic pathways also contribute to glioma susceptibility. The above-mentioned immune disorders have also been associated with genetic variation in the major histocompatibility complex (MHC) region [7] [8] [9] , which contains human leukocyte antigen (HLA) genes encoding cell-surface molecules responsible for antigen Abstract Although genome-wide association studies have identified several susceptibility loci for adult glioma, little is known regarding the potential contribution of genetic variation in the human leukocyte antigen (HLA) region to glioma risk. HLA associations have been reported for various malignancies, with many studies investigating selected candidate HLA polymorphisms. However, no systematic analysis has been conducted in glioma patients, and no investigation into potential non-additive effects has been described. We conducted comprehensive genetic analyses of HLA variants among 1746 adult glioma patients and 2312 controls of European-ancestry from the GliomaScan Consortium. Genotype data were generated with the Illumina 660-Quad array, and we imputed HLA alleles using a reference panel of 5225 individuals in the Type 1 Diabetes Genetics Consortium who underwent high-resolution HLA typing via next-generation sequencing. Case-control comparisons were adjusted for population stratification using ancestry-informative principal components. Because alleles in different loci across the HLA region are linked, Electronic supplementary material The online version of this article (doi:10.1007/s11060-017-2569-7) contains supplementary material, which is available to authorized users. presentation and immune response modulation. HLA variation has also been associated with risk of several cancers, including chronic lymphocytic leukemia, lung squamous cell carcinoma, ovarian, breast, cervical, and nasopharyngeal cancers [10] . In view of these prior findings, we hypothesized that variants in the HLA region may also potentially be associated with glioma risk.
Genome-wide association studies (GWAS) have identified several susceptibility loci for glioma [11] [12] [13] , although none were in the HLA region on chromosome 6. However, genetic variation and haplotype structure in HLA genes is not wellcaptured by standard genome-wide SNP arrays due to the unique characteristics of sequence and copy-number variation across the MHC region. Furthermore, glioma GWAS to-date have only examined additive models, which assume a linear increase in effect per risk allele on the log-odds scale and therefore have limited power to detect non-additive effects deviating from this linear relationship. Given the observation of widespread non-additive and epistatic effects within the HLA region for a number of autoimmune diseases [14] [15] [16] , non-additive effects in this gene-dense region of highly polymorphic, multi-allelic variants may also play an important role in glioma risk.
Several previous studies have examined HLA with respect to glioma risk, yielding inconsistent results across both HLA class I and II genes [17] [18] [19] [20] [21] [22] . However, prior analyses were generally limited in size (with the largest study involving 255 cases) and scope (selective candidate genotyping was commonly performed, resulting in a limited number of variants being interrogated). Furthermore, earlier studies were often limited by the resolution of HLA genotyping, assessing two-digit resolution that only uniquely identifies serological groups rather than at the four-digit resolution that identifies polymorphisms at the amino acid level. Long-range HLA supertypes (extended haplotypes) have also been ignored. Given that specific amino acid polymorphisms within the same serological group can have differing associations with the same autoimmune diseases, as observed in Type 1 diabetes [23] , multiple sclerosis [24] and others, a more comprehensive investigation of HLA variants using high-resolution genotyping data may improve the detection of glioma susceptibility variants. We therefore examined associations between HLA polymorphisms and glioma risk under both additive and non-additive models in a large case-control study of glioma patients with high-resolution HLA imputation data.
Materials and methods

Samples
GliomaScan is a consortium of studies comprising 1856 adult glioma patients and 4955 controls, with study periods ranging from 1974 to the present. Individual-level genotype and phenotype data were downloaded from the Database of Genotypes and Phenotypes (dbGaP, Study Accession phs000652.v1.p1) after review and approval by the NCI Data Access Committee. Information on case ascertainment, genotyping, and quality control are described in the Supplementary Materials.
Imputation of HLA genotypes
Four-digit classical HLA alleles were imputed in the three main class I genes (HLA-A, HLA-B, and HLA-C) and in five class II genes (HLA-DRB1, -DPA1, -DPB1, -DQA1, and -DQB1) with SNP2HLA [25] , using a reference panel of 5225 individuals of European ancestry from the Type 1 Diabetes Genetics Consortium who underwent high-resolution HLA typing via next-generation sequencing [26] .
Imputation of loci outside the HLA region was carried out as described in the Supplemental Materials.
Selection of alleles and individuals for analysis
For the MHC-wide association analyses, we restricted to the commonly observed (i.e. frequency ≥5% of the total study population) classic four-digit HLA class I and II alleles among 1746 cases and 2312 controls of European ancestry. For the non-additive effect analyses, we created multigene haplotypes by combining phased four-digit classical alleles from genes DRB1, DQA1, and DQB1, chosen because their alleles are in strong linkage disequilibrium, allowing associations for multiple loci to be tested without loss of power due multiple test corrections. For the multigene haplotype analyses of DRB1-DQA1-DQB1 haplotypes, we restricted to individuals who had two best-guess haplotype variants at each of the three genes, and haplotypes with a frequency ≥5% of the total study population. Supplementary Fig. 1 illustrates the selection of HLA variants and individuals in this study.
Statistical analyses
To analyze the additive effects of individual class I and II HLA variants on glioma risk, we performed MHC-wide logistic regression analyses using the SNP2HLA imputed allele dosage data, and the "logistic" command in PLINK 1.9 [27] , adjusting for the first five ancestry-informative principal components generated by Eigenstrat [28] . Additive effects of multigene haplotypes on glioma risk were estimated using the best-guess multigene haplotypes, and the glm command in R.
To investigate non-additive associations in class I and II alleles, and multigene haplotypes, we used dominance-effect models; in addition to the additive term capturing the dosage effect of a haplotype (i.e. 0,1,2 copies), a dominant term was included to capture any deviation from the additive scenario. The dominance model was compared against the baseline additive model for each haplotype by calculating the change in deviance (−2 × the difference in log likelihood) between models, which follows a χ 2 distribution with 1 degree of freedom. The P value for the χ 2 test represents the significance in improvement of fit of the model after including the dominance term for a given haplotype. Bonferroni-adjusted significance thresholds were used to correct for multiple haplotype tests. All analyses were performed for individual genotypes and repeated for the multigene haplotypes. We also tested for general non-additive effects at the DRB1-DQA1-DQB1 multigene locus by simultaneously including the additive and dominance terms for all DRB1-DQA1-DQB1 variants in a global regression model (Supplementary Materials).
We examined the glioma risk of carriers of each haplotype compared to non-carriers, stratified by homozygous and heterozygous status for each haplotype. Under an additive model of association, the log-odds ratio of being a carrier of a given haplotype compared to non-carriers in heterozygotes should be half of that in homozygotes (i.e. the odds ratio of heterozygous carriers should be the square root of that of homozygous carriers). Deviation from this linear relationship can indicate the presence of non-additivity.
We tested for interaction effects as potential explanations for any observed departures from additivity in the multigene association analyses (Supplementary Materials).
For haplotypes with effects observed in the non-additive analyses, we performed conditional analyses further adjusting for 37 previously observed GWAS SNPs to assess any attenuation of non-additive effects [12] .
Additional sex-stratified analyses were performed because sex-specific differences were previously observed for the incidence of both glioma [1] and autoimmune disorders [29] . Stratified analyses by age of diagnosis (<50, ≥60), and carrier status of the risk variant (G) for SNP rs55705857 were performed because of their previously observed associations with tumor grade and IDH-status [30, 31] , allowing these variables to serve as proxies for lower-grade glioma. The age stratification cutoffs were chosen based on available data on age groups and to maximize the prediction of tumor grade by age [32] .
Equations for the association analyses using the additive, dominance, and interaction effect models are described in detail in the Supplementary Materials.
Results
MHC-wide allele association with glioma risk
Among the 20 class I alleles and 29 class II alleles tested, three HLA variants: HLA-B*4001, HLA-DRB1*1302 and HLA-DPB1*0101 showed nominally significant protective effects against glioma (P < 0.05) under an additive model, but no associations were detected after Bonferroni correction (Supplementary Table 1 ).
Multigene haplotype association with glioma risk
Nine HLA-DRB1-DQA1-DQB1 haplotypes had frequencies ≥5%, consisting of 99% of the multigene haplotypes in the study population (among individuals with allele frequencies ≥5% for DRB1, DQA1, and DQB1). A total of 887 cases and 1211 controls had common diploid multigene haplotype information fulfilling the inclusion criteria. None of the haplotypes were associated with glioma risk under the additive model for individually modeled haplotype variants, nor under the global additive model for all haplotype variants. Association estimates and haplotype frequencies for the multigene haplotypes are summarized in Supplementary Table 2 . 
Dominance model analyses
Association analyses comparing homozygous vs heterozygous carriers
Individuals that were heterozygous for the HLA-DRB1*1501-DQA1*0102-DQB1*0602 multigene haplotype were at increased risk of glioma compared with non-carriers (Table 1) , with an adjusted odds ratio (OR) of 1.23 (95% CI 1.01-1.49; P = 0.040). Homozygous carriers of the haplotype were at modestly decreased risk of glioma compared with non-carriers (OR 0.64; 95% CI 0.40-1.01; P = 0.057). These estimates were not significant after Bonferroni correction (P < 0.006), although they were consistent with the estimates from the non-additive analysis of the DRB1*1501-DQA1*0102-DQB1*0602 haplotype using the χ 2 tests of improvement of fit. Frequency counts showing the enrichment of glioma cases for heterozygous carriers of the HLA-DRB1*1501-DQA1*0102-DQB1*0602 haplotype are shown in Table 2 . Associations for this haplotype, along with all other multigene haplotypes, are displayed in Fig. 1 as a scatterplot, and in Supplementary Fig. 2 (Supplementary Fig. 3 ). No differences were observed between homozygous and heterozygous carriers of HLA class I alleles (data not shown).
Interaction model analyses
We examined interaction models of the HLA-DRB1*1501-DQA1*0102-DQB1*0602 haplotype paired with each of the remaining eight haplotypes ( 
Stratified analyses
No differences were observed when analyses were stratified by sex (data not shown).
In the age-stratified analyses, inclusion of the dominance term improved the model fit for HLA-DRB1*1501-DQA1*0102-DQB1*0602 for younger subjects (P improve = 0.05) but not older subjects (P improve = 0.35). However, only four controls and 0 cases were homozygous carriers of the haplotype among younger subjects, resulting in unstable point estimates of the additive and dominance terms due to collinearity.
In the rs55705857-stratified analyses, inclusion of the dominance term improved the model fit for both lowgrade variant carriers (P improve = 0.021) and non-carriers (P improve = 0.009), with a larger dominance term estimate of carriers (OR 2.00, 95% CI 1.10-4.26) compared to noncarriers (OR 1.54, 95% CI 1.16-2.03).
Discussion
This is the most comprehensive study to date of the association between HLA variants and glioma risk, and the first to systematically compare additive and non-additive associations, which enabled the identification of effects not previously described. We observed no additive effect, and a non-additive dominance effect for HLA-DRB1*1501-DQA1*0102-DQB1*0602, a multigene haplotype present in ~40% of all study subjects. The non-additive effect was not attenuated in conditional analyses adjusted for known risk SNPs identified in prior GWAS, suggesting that the effect is independent of previously described genetic associations. Our association estimates suggest that being a homozygous carrier of HLA-DRB1*1501-DQA1*0102-DQB1*0602 is protective against glioma, and that being a heterozygous carrier confers increased risk, with the positive dominance effect at least in part explained by the interaction with HLA-DRB1*0401-DQA1*0301-DQB1*0301.
Among our three nominally significant MHC-wide associations, two have been previously described in association with glioma at the two-digit resolution level. Namely, our finding that HLA-B*4001 and HLA-DRB1*1302 were protective against glioma was consistent with prior observations that HLA-B*40 and HLA-DRB1*13 were enriched among the control group [17, 18, 21] , although the association was not significant in those prior studies and the opposite direction of effect was observed in another study [22] . Although a previous GWAS found that rosacea (recently linked to glioma risk in a large Danish cohort [5] ) is associated with three HLA alleles found to be in high linkage disequilibrium in our study (DRB1*0301, DQA1*0501, and DQB1*0201) [8] , we did not observe these alleles to be associated with glioma risk, suggesting that the gliomarosacea link is not likely due to shared HLA risk variants with pleiotropic effects.
HLA-DRB1*1501-DQA1*0102-DQB1*0602 is sometimes more simply referred to as the DR15 haplotype, a long-range HLA haplotype frequently observed in Northern Europeans (also known as the ancestral DR2 haplotype) [33] . The Northern European origin of this haplotype is intriguing, as its distribution may contribute to the lower incidence of gliomas observed in individuals of African ancestry [1] . Previous disease associations observed with this haplotype (and components of the haplotype) include several autoimmune disorders such as narcolepsy, systemic lupus erythematosus, type 1 diabetes, and multiple sclerosis [34 -37] . Additionally, the DRB1*1501-DQB1*0602 haplotype has been previously implicated in cervical neoplasia risk, with heterogeneity of effect by human papillomavirus infection type [38] . Prior literature describing the role of viral infections, such as human cytomegalovirus [39] and varicella-zoster [40] , on the pathogenesis of gliomas further highlights the relevance of investigating HLA variants in association with glioma. Our primary finding that multigene haplotype HLA-DRB1*1501-DQA1*0102-DQB1*0602 was associated with glioma risk in a non-additive manner may, in part, explain prior conflicting reports on the association between glioma risk and DRB1*15. Namely, our finding of the increased risk for glioma in heterozygous carriers of HLA-DRB1*1501-DQA1*0102-DQB1*0602 is consistent with studies reporting increased glioma risk associated with DRB1*15 [18, 22] , with the multigene haplotypes including both DRB1*15 and DQB1*06 also conferring increased glioma risk. Other studies detected no association between DRB1*15 and glioma risk [17, 19, 20] . The previously reported association between increased glioma risk and DQB1*06 [18, 19, 22] is consistent with our finding that DQB1*0602 (in linkage disequilibrium with DRB1*1501) increased glioma risk in heterozygous carriers. We posit that the method of comparing allele frequency distribution between cases and controls used in prior studies is not as well powered to detect non-additive effects, particularly in light of the possible opposing effect directions we observed in homozygous and heterozygous carriers, contributing to the inconsistent evidence in the prior literature. Notably, we would also have detected no association had we chosen to analyze the data simply as a χ 2 test of haplotype variant frequency distributions between cases and controls (P = 0.8239), due to the misspecification of the model. Our findings reinforce the idea that non-additive effects in the MHC region are an important area of investigation, particularly as necessary functional redundancy in the immune system is hypothesized as a driver of non-additive effects [41] , and such effects have been observed in many autoimmune-related disorders previously linked to glioma risk [14, 15] .
Our observation of a synergistic increase in glioma risk associated with the interaction between HLA-DRB1*1501-DQA1*0102-DQB1*0602 and HLA-DRB1*0401-DQA1*0301-DQB1*0301 may be partially driven by the dominance effect detected in the dominance model. However, this diplotype does not constitute a large portion of the heterozygous individuals, so it is not likely to be a main driver of the observed dominance effect. While it is not apparent why heterozygosity of the HLA-DRB1*1501-DQA1*0102-DQB1*0602 haplotype would increase glioma risk, prior association studies of HLA haplotypes in autoimmune disorders such as Type 1 diabetes, lupus, narcolepsy, ulcerative colitis, celiac disease, rheumatoid arthritis, and psoriasis show both increased or decreased risk in homozygotes compared to heterozygotes [14, 15, [34] [35] [36] , suggesting that the exact nature of non-additivity is allele-and disease-specific.
Although we were unable to directly assess the observed non-additive effect separately among glioma histological subtypes (an important clarification given known differences between subtypes with regards to incidence, biology, natural history and association with genetic variants [12, 13] ), we used age of diagnosis and rs55705857 genotype as proxies of tumor grade and histology [30, 32, 33] . Both stratified analyses suggest that the non-additive effect of HLA-DRB1*1501-DQA1*0102-DQB1*0602 is stronger in low-grade glioma, although several caveats merit mentioning. The age-stratified analysis was limited by the smaller sample size of the younger age group (n = 119 vs. n = 637 among haplotype carriers with available age of diagnosis data). Furthermore, although the magnitude of the dominance term estimate suggested a stronger association in carriers of the low-grade variant, we observed a more significant P improve in non-carriers. This discrepancy in effect size versus statistical significance is likely due to the larger sample size of cases not carrying the low-grade variant (n = 717 vs. n = 170 carriers). This observation suggesting differential association with immune-related variants by glioma type is consistent with a prior study observing stronger allergy associations in non-glioblastoma tumors [42] , although other studies have also suggested no difference by subtype [6] , and slightly stronger effects in highgrade gliomas [4] . Future studies incorporating histopathology and tumor molecular markers (e.g. IDH and 1p/19q co-deletion status) are needed to clarify any subtype-specificity of HLA risk variants.
Our study is limited by its focus on subjects of European ancestry, and as such may not be generalizable to subjects with other ancestral backgrounds. More work is necessary to replicate our findings, and extend the investigations to non-European subjects. GliomaScan did not include information on other disease status such as diagnoses of atopic and autoimmune diseases, which would have allowed further clarification of whether the association between glioma and immune-related diseases have a shared genetic basis in the HLA region. Finally, additional studies of potential interactions between HLA variants and viral infection status on conferring glioma risk are warranted to expand this line of inquiry.
In summary, we observed a dominance effect on glioma risk for a common HLA class II multigene haplotype with a frequency of ~40% of our study subjects. Future studies are needed to validate the significance of this haplotype association and to identify the causal mechanisms underlying the apparent non-additive effects.
